Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Pre-Mkt 01-21 05:32:19 EST

1.99

-0.05

-2.45%

High2.04	Low1.97	Vol854.26K
Open2.01	D1 Closing2.04	Amplitude3.68%
Mkt Cap96.13M	Tradable Cap86.52M	Total Shares48.31M
T/O1.71M	T/O Rate1.96%	Tradable Shares43.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":1.99,"timestamp":1768942800000,"preClose":2.04,"halted":0,"volume":854260,"delay":0,"changeRate":-0.024509803921568648,"floatShares":43475193,"shares":48307896,"eps":-2.197613,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"01-21 05:32:19 EST","open":2.01,"high":2.04,"low":1.965,"amount":1705513.175652,"amplitude":0.036765,"askPrice":2.15,"askSize":100,"bidPrice":1.94,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-2.197613,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769005800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.99,"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":1.99,"latestTime":"19:58 EST","volume":5318,"amount":10719.7896,"timestamp":1768957129947,"change":0.03,"changeRate":0.015075,"amplitude":0.020101},"volumeRatio":1.1517195300446494,"impliedVol":0.3621,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/SAVA/tweets","defaultTab":"tweets","newsList":[{"id":"2603684212","title":"Cassava Sciences announces publication of Phase 3 results for simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684212","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684212?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:10","pubTimestamp":1768309841,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) announced publication of the article Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s diseas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-announces-publication-of-phase-3-results-for-simufilam-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-announces-publication-of-phase-3-results-for-simufilam-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4007","BK4547","SAVA"],"gpt_icon":0},{"id":"2603875684","title":"Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603875684","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603875684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309200,"startTime":"0","endTime":"0","summary":"As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ stud","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217761/8339/en/Cassava-Announces-Publication-of-Peer-Reviewed-Phase-3-Results-for-Simufilam-in-Alzheimer-s-Disease-in-the-Journal-of-Prevention-of-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4585","CNS","BK4135","ETH","BK4601","BK4007","SAVA"],"gpt_icon":0},{"id":"2595790834","title":"SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2595790834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595790834?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:17","pubTimestamp":1767100620,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Dec.  30, 2025  (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (\"NeuroThera\"), a clinical-stage p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211377/0/en/SciSparc-Neurothera-Labs-Granted-Patent-by-Israeli-Patent-Office-for-its-Proprietary-Opioid-Based-Patent-Family-to-Enhance-Pain-Relief-and-Reduce-Side-Effects.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4585","BK4007","SAVA"],"gpt_icon":0},{"id":"2593904574","title":"Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2593904574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593904574?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494859,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT02P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4547","SAVA","BK4585","BK4588"],"gpt_icon":0},{"id":"2593449042","title":"Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449042?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494859,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT02P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2593049049","title":"Cassava Sciences Settles Securities Class Action for $31.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2593049049","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593049049?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494834,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action litigation filed in 2021 in the United States District Court for the Western District of Texas. The company will pay $31.25 million to resolve all claims from plaintiffs who purchased or acquired Cassava common stock or call options, or sold put options, between September 14, 2020, and October 12, 2023. The settlement fully releases Cassava from all related claims and does not constitute an admission of fault or wrongdoing. The company had previously reserved the entire settlement amount as a loss contingency in the second quarter of 2025. With the settlement, Cassava plans to focus on developing simufilam for TSC-related epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL62WWsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK4007","SAVA","BK4112","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","NDAQ","SG9999014039.USD","BK4547","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2593854418","title":"Cassava Announces Agreement to Settle Securities Class Action Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2593854418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593854418?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Dec.  23, 2025  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209829/8339/en/Cassava-Announces-Agreement-to-Settle-Securities-Class-Action-Litigation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA","BK4547","BK4588","BK4135","CNS","BK4007","BK4585"],"gpt_icon":0},{"id":"2593458615","title":"Cassava Sciences Names Dawn C. Bir to Compensation Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458615","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458615?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:10","pubTimestamp":1766437810,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has amended its previous filing to announce that on December 18, 2025, Dawn C. Bir was appointed as a member of the Board’s Compensation Committee, effective immediately. This update corrects the earlier report, which did not include her committee assignment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL6TPx78:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","SAVA","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2592987061","title":"Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2592987061","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592987061?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:49","pubTimestamp":1766155771,"startTime":"0","endTime":"0","summary":"(Corrects the third paragraph to note the personal income and outlays report being rescheduled.)US stock futures were mixed in Friday's premarket session, with investors hopeful of a federal rate cut ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9f9ae861e0d5137ca1db9f83a4575ef","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVIW.SI",".DJI","BK4585","SQQQ","BK4007",".SPX","BK4116","WYFI","MYMmain","UDOW","MNQmain","DJX","QLD","BK4211","QID","MGRT","USJW.SI","DXD","DOG","DDM","TQQQ","TSYW.SI","YCBD","VMAR","BK4547","HOPE","BK4190",".IXIC","SAVA","SDOW","PSQ","USAW.SI","ISBC","NQmain","BK4139","BK4588","PBM"],"gpt_icon":1},{"id":"2592180462","title":"Stocks to Watch: Nike, Cassava Sciences, KB Home","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592180462?lang=en_us&edition=fundamental","pubTime":"2025-12-19 07:39","pubTimestamp":1766101140,"startTime":"0","endTime":"0","summary":"Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday.Cassava Sciences said the FDA had placed a hold on its trial for a drug to treat epilepsy. Shares slid 13% to $2.49 after the bell.KB Home delivered fewer homes and recorded a lower profit in its most recent quarter. The stock declined 3.6% to $60.50.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKE","BK4588","LU1267930573.SGD","BK4558","LU0029864427.USD","BK4581","BK4207","BK4585","LU0708994859.HKD","LU0889566641.SGD","LU0128525929.USD","IE00BYQQ9H92.USD","BK4534","LU1267930813.SGD","LU1303367103.USD","BK4533","LU0823411888.USD","LU0310800379.SGD","KBH","SAVA","LU0792757196.USD","LU0786609619.USD","BK4088","LU2098885051.SGD","BK4146","BK4007","BK4561","IE00BFXG0V08.USD","BK4566","BK4547","KB"],"gpt_icon":1},{"id":"2592618256","title":"Cassava Sciences Inc - on Dec 15, FDA Places Full Clinical Hold on Cassava's Trial - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618256?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095454,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO18P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4007","BK4547","SAVA"],"gpt_icon":0},{"id":"2592182683","title":"Cassava Sciences: Not Expected to Initiate Proof-of-Concept Clinical Trial for Simufilam in Tsc-Related Epilepsy in H1 2026 as Previously Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182683?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095454,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO18P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","SAVA","BK4007","BK4547"],"gpt_icon":0},{"id":"2592182530","title":"FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182530","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182530?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:03","pubTimestamp":1766095387,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. is facing a regulatory setback after the U.S. Food and Drug Administration  placed a full clinical hold on its proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex -related epilepsy. The FDA requires Cassava to provide additional pre-clinical data and modify the trial protocol before the hold can be lifted. As a result, the company no longer expects to begin the clinical trial in the first half of 2026, and the revised timeline will depend on how quickly Cassava can address the FDA’s concerns and complete the regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4hX68f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4547","BK4007","SAVA","BK4588"],"gpt_icon":0},{"id":"2592431159","title":"Cassava Sciences Awards 2025 Cash Bonuses to Top Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2592431159","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592431159?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:13","pubTimestamp":1766005984,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has announced cash bonus awards for its named executive officers for the 2025 calendar year. Richard J. Barry, President and Chief Executive Officer, will receive a bonus of $355,000, while Eric J. Schoen, Chief Financial Officer, will receive $215,000. The bonuses are based on performance measures focused on exploring the use of simufilam in Tuberous Sclerosis Complex -related epilepsy, building a team with expertise in TSC-related epilepsy, and effective budgeting and expense management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5G2d57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4547","BK4007","SAVA"],"gpt_icon":0},{"id":"2588973046","title":"BRIEF-Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588973046","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588973046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:51","pubTimestamp":1764766305,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC FilingDec 3  - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES INC - FDA REQUIRES ADDITIONAL INFORMATION FROM CASSAVA FOR CLINICAL STUDY - SEC FILINGCASSAVA SCIENCES INC - PREPARES TO INITIATE PROOF-OF-CONCEPT STUDY IN FIRST HALF OF 2026 FOR SIMUFILAM - SEC FILINGCASSAVA SCIENCES INC - EXPECTS FORMAL LETTER FROM FDA DETAILING ISSUES ON CLINICAL TRIAL FOR SIMUFILAM - SEC FILINGSource text: [ID:n0001437749-25-036710]Further company coverage: SAVA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","SAVA","BK4585","BK4547"],"gpt_icon":0},{"id":"2588048157","title":"Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048157","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588048157?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:27","pubTimestamp":1764761268,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has submitted an investigational new drug  application to the U.S. Food and Drug Administration  for a proposed proof-of-concept clinical trial of simufilam in tuberous sclerosis complex -related epilepsy. The FDA has requested additional information from the company to assess potential risks and support the initiation of the study. Cassava Sciences expects to receive a formal letter from the FDA detailing the required steps to address these issues and plans to work collaboratively with the agency, aiming to begin the trial in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL9d5w2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2586409354","title":"Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409354","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409354?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:06","pubTimestamp":1764104812,"startTime":"0","endTime":"0","summary":"Robert Eugene Anderson Jr., a director of Cassava Sciences Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLCDWBc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4547","BK4585","SAVA"],"gpt_icon":0},{"id":"2586640692","title":"Cassava Sciences Gains on Insider Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2586640692","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586640692?lang=en_us&edition=fundamental","pubTime":"2025-11-26 04:45","pubTimestamp":1764103539,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) climbed as much as 12.1% intraday on Tuesday after a filing showed chief executive officer Richard Barry bought 150,000 shares on Nov. 20 for about $414,000. He now indirectly controls 938,060 shares.Price: 3.08, Change: +0.18, Percent Change: +6.03","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAVA","BK4588","BK4585","BK4547","BK4007"],"gpt_icon":0},{"id":"2586949086","title":"Cassava Sciences CEO Richard Barry Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586949086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586949086?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:02","pubTimestamp":1764018167,"startTime":"0","endTime":"0","summary":"Richard Barry, President & CEO, reported an acquisition of common shares of Cassava Sciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2SwLgq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cassava Sciences CEO Richard Barry Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4585","BK4547","SAVA"],"gpt_icon":0},{"id":"2585167086","title":"Cassava Sciences CEO Makes Bold Move with Major Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167086","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167086?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:12","pubTimestamp":1763691149,"startTime":"0","endTime":"0","summary":"New insider activity at Cassava Sciences ( ($SAVA) ) has taken place on November 20, 2025. President & CEO Richard Barry has made a significant inv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cassava-sciences-ceo-makes-bold-move-with-major-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cassava-sciences-ceo-makes-bold-move-with-major-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4547","SAVA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":-0.0851},{"period":"3month","weight":-0.4622},{"period":"6month","weight":-0.2103},{"period":"1year","weight":-0.2764},{"period":"ytd","weight":0.0051}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.143985},{"month":2,"riseRate":0.44,"avgChangeRate":0.027406},{"month":3,"riseRate":0.44,"avgChangeRate":0.008402},{"month":4,"riseRate":0.6,"avgChangeRate":0.05975},{"month":5,"riseRate":0.44,"avgChangeRate":0.038503},{"month":6,"riseRate":0.44,"avgChangeRate":-0.019669},{"month":7,"riseRate":0.48,"avgChangeRate":0.007146},{"month":8,"riseRate":0.5,"avgChangeRate":0.01628},{"month":9,"riseRate":0.615385,"avgChangeRate":0.114687},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.039373},{"month":11,"riseRate":0.576923,"avgChangeRate":-0.009282},{"month":12,"riseRate":0.346154,"avgChangeRate":0.016148}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}